7087-60-7

Basic information

• Product Name: 1-fluoro-3-methoxy-5-nitrobenzene
• Synonyms: 1-fluoro-3-methoxy-5-nitrobenzene;3-Fluoro-5-nitroanisole
• CAS NO: 7087-60-7
• Molecular Formula: C₇H₆FNO₃
• Molecular Weight: 171.1258432
• Mol File: 7087-60-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 244.5°Cat760mmHg
• Flash Point: 101.7°C
• Appearance: /
• Density: 1.321g/cm³
• Vapor Pressure: 0.0473mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 1-fluoro-3-methoxy-5-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-fluoro-3-methoxy-5-nitrobenzene(7087-60-7)
• EPA Substance Registry System: 1-fluoro-3-methoxy-5-nitrobenzene(7087-60-7)

Safety Data

• Hazardous Substances Data: 7087-60-7(Hazardous Substances Data)

Usage

General Description

1-fluoro-3-methoxy-5-nitrobenzene is an organic compound with the chemical formula C7H6FNO3. It is a pale yellow solid with a molecular weight of 167.125 g/mol. This chemical is used in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in organic chemistry. The compound has potential health hazards, as it is a skin and eye irritant, and may cause respiratory irritation. It should be handled with caution and proper protective equipment.

InChI:InChI=1/C7H6FNO3/c1-12-7-3-5(8)2-6(4-7)9(10)11/h2-4H,1H3

Upstream product

• 2369-10-0 3-fluoro-5-nitrophenol 
• 77-78-1 dimethyl sulfate 
• 586-10-7 3-methoxy-5-nitroaniline 
• 110-46-3 isopentyl nitrite 
• 67-56-1 methanol 
• 2265-94-3 1,3-difluoro-5-nitrobenzene 

Downstream Products

• 16147-07-2 1,3-dimethoxy-5-nitrobenzene 
• 2339-58-4 3-fluoro-5-methoxyphenylamine 
• 93398-05-1 4-(3-methoxy-5-nitrophenyl)morpholine 
• 939771-60-5 3-fluoro-5-iodophenol 
• 1167056-58-7 1-fluoro-3-iodo-5-methoxybenzene 
• 1333950-17-6 C₂₃H₁₆FN₅O 
• 1352622-33-3 C₁₆H₁₀FN₃O 
• 2369-10-0 3-fluoro-5-nitrophenol 

Relevant articles and documents

Novel pazopanib derivatives and pharmaceutical composition comprising the same

The present invention relates to novel pazopanib derivatives or a salt thereof having inhibition activities of angiogenesis and epidermal growth factors at the same time, and to a pharmaceutical composition comprising the same as an active ingredient. The pazopanib derivatives have inhibition activities of angiogenesis and epidermal growth factors at the same time unlike pazopanib, thereby more effectively treating and preventing EGFR-related cancer diseases such as lung cancer, colon cancer or breast cancer through a multiple aim target, and effectively treating and preventing non-small-cell lung cancer which Iressa or Tarceva cannot have an effect on.COPYRIGHT KIPO 2017

Development of CXCR3 antagonists. Part 4: Discovery of 2-amino-(4-tropinyl)quinolines

The synthesis and biological evaluation of a novel series of 2-aminoquinoline substituted piperidines and tropanes incorporating a homotropene moiety is herein described. The series exhibits potent antagonism of the CXCR3 receptor and superior physicochem